Immune cells and gut bacteria in people with idiopathic nephrotic syndrome
Measures blood immune cells and gut bacteria in people with idiopathic nephrotic syndrome.
Key facts
- Who runs it
- Nantes University Hospital
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- INS, B Cells and Microbiota
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 18 Jan 2022
- Expected to end
- 18 Jan 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Measurement of blood immune populations and microbiota distribution.
- Record updated
- 3 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a flare of nephrotic syndrome, a kidney condition that makes the body lose protein in the urine. It compares idiopathic nephrotic syndrome (no known cause) with other kidney diseases of this type. It studies blood immune cells and gut bacteria.
- Age
- 12 years and older
- Sex
- All sexes
- Disease stage
- In a nephrotic flare: urine protein above 3g per 24h, or a urine protein/creatinine ratio above 3, or as judged by the doctor. Main group: idiopathic nephrotic syndrome. A smaller group has nephrotic syndrome from IgA, GEM type or another kidney filter disease.
- Earlier treatment
- People cannot join if they take immunosuppressants or corticosteroids above 10 mg/d.
- Biomarker or test result
- Urine protein above 3g per 24h, or urine protein/creatinine ratio above 3, unless the doctor decides otherwise.
Main reasons for not taking part
- Past flares that did not respond to corticosteroid treatment
- Weight under 50 kg (110 lb)
- Pregnant women
- People under guardianship or curatorship
- Current immunosuppressant treatment or corticosteroids above 10 mg/d
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patient treated in participating centers
- In nephrotic attack, defined biologically by:; Proteinuria > 3g 24h or A proteinuria/creatinuria ratio > 3 or Defined at the discretion of the clinician; Non inclusion Criteria :
- Patient with a history of NIS flare-ups resistant to corticosteroid therapy
- Patient treated with immunosuppressant
- Patient treated with corticosteroids > 10 mg/d
- Weight <50 kg
- Pregnant woman
- Patient under guardianship / curatorship
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Idiopathic nephrotic syndrome (NIS) is a clinical entity defined by the association of selective albuminuria, hypoalbuminemia, and nonspecific glomerular lesions (lesions minimal glomerular (LGM) or segmental and focal hyalinosis (HSF). The complication of this kidney disease is the progression towards chronic renal failure and in case of kidney transplantation, its immediate recurrence on the graft . The origin of this syndrome is unknown but a number of clinical observations tend to show an involvement of immune system. A link has been highlighted between atopy, diet and nephrotic flare-ups. The speed of recurrence of this initial disease on the graft and the observation of remissions obtained after treatment by plasma exchange or immunoadsorptions support the presence of a pathogenic plasma factor. Anti-CD20 treatments depleting B lymphocytes has made it possible to favorably treat a number of patients. Dysfunction of regulatory T cells has also been shown in SNI patients. This modification seems linked to allergies and could be due to an aberrant microbiota. The hypothesis of causality between dysbiosis, alteration lymphocyte and triggering of an SNI was mentioned recently. Two studies have shown intestinal dysbiosis in pediatric SNI/LGM, with reduction of T circulating regulators
The 2 groups in the trial
- Patient with nephrotic syndrome idiopathic
nephrotic INS patients in primary visit: harvesting of 27.5 ml supplementary blood, 40 mlurine and feces at inclusion visit and at 3 months. No intervention, no treatment administration other than usual/routine INS treatment.
Treatment: Measurement of blood immune populations and microbiota distribution.
- Patient with nephrotic syndrome no idiopathic, IgA or GEM type or other glomerulopathy
At least 10 NS no idipathic patients: harvesting of 27.5 ml supplementary blood, 40 ml urine and feces at inclusion visit and at 3 months. No intervention, no treatment administration other than usual/routine care treatment.
Treatment: Measurement of blood immune populations and microbiota distribution.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Controlled Multicenter Epidemiological Study of Peripheral Leukocyte Populations and Microbiota in Patients With Idiopathic Nephrotic Syndrome (INS)
- Plain-language title
- Immune cells and gut bacteria in people with idiopathic nephrotic syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 3 March 2026